Foresite Capital — 2016 Investments
5 investments dated 2016 · listed companies and verified rows first · show all
Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.
BiotechHealthtechWarminster, US
William H. Collier(President and Chief Executive Officer)Gaston Picchio(Chief Development Officer)Michael J. McElhaugh(Chief Business Officer)David C. Hastings(Chief Financial Officer)Michael J. Sofia(Chief Scientific Officer)Elizabeth Howard(Executive Officer)
Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.
BiotechHealthtechHampton, US
Anthony S. Marucci(Executive Officer, Director)Avery W. Catlin(Executive Officer)Timothy M. Shannon, M. D.(Director)
BoardRichard van den Broek(Director)Herbert J. Conrad(Director)Karen Shoos(Director)
BiotechFort Washington, US
Rebecca Taub(Executive Officer, Director)
BoardFred Craves(Director)Lionel Carnot(Director)
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)Gregory Lumpkin(Executive Officer)Ashleigh Palmer(Director)Matthew Rieke(Director)
BoardRichard Kollender(Director)Martin Edwards(Director)
Board seatJames Tananbaum· per SEC Form D · $2M raise · filed Feb 2016
Co-investorsMVM Life Science Partners
Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.
BiotechBoston, US
James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)
Co-investorsBay City CapitalCycad Group LLCNXT Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.